We have shown that elevated expression of HER3 renders HER2-overexpressing breast cancer cells resistant to tamoxifen [17], HER2-targeted therapy (trastuzumab/Herceptin and lapatinib) [18, 19], and the chemotherapeutic agent paclitaxel [20]. Here, ERBB3 is linked to breast carcinoma.